Colchicina, perspectivas de un viejo amigo para la reumatología en la COVID-19: una revisión exploratoria

Eduardo Tuta-Quintero, María Camila Vega-Corredor, Laura Sofía Perdomo-Rodríguez, Juan Pimentel

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva


Introduction: Colchicine is widely used to treat inflammatory diseases such as gout and Mediterranean fever. Due to its immunomodulatory capacity, it could play an important role in the treatment of COVID-19. Objective: To explore the current available medical evidence, published until 28 December 2020, regarding the efficacy and safety of colchicine in the treatment of patients with confirmed SARS-CoV-2 infection. Material and methods: Scoping review of the literature that included PubMed and Scopus. Records of clinical trials and publications with empirical data (observational and experimental studies) in English and Spanish were included. Results: A total of 33 clinical trials and 6 publications were found: prospective (n = 2) and retrospective (n = 2) cohort studies, randomised clinical trials (n = 1) and case-control studies (n = 1). The total number of participants in the trials is 46,324 individuals, 73% (24/33) of the studies are recruiting participants and 51% (17/33) are phase 3 studies. Conclusions: One clinical trial reports a decrease in prognostic inflammatory markers and length of hospital stay in SARS-CoV-2 infection. The ongoing clinical trials will clarify the efficacy and safety of colchicine for the management of patients with COVID-19.

Título traducido de la contribuciónColchicine, an old friend's perspectives for rheumatology in COVID-19: a scoping review
Idioma originalEspañol
PublicaciónRevista Colombiana de Reumatologia
EstadoEn prensa - 2021

All Science Journal Classification (ASJC) codes

  • Reumatología

Citar esto